Alx Oncology Holdings INC (ALXO) — 8-K Filings

8-K Filings (14)

• 8-K Filing — Apr 13, 2026
• ALX Oncology Files 8-K: Director Changes and Officer Appointments — Sep 12, 2025 Risk: medium
  ALX Oncology Holdings Inc. filed an 8-K on September 11, 2025, reporting on the departure of directors, election of directors, appointment of officers, and comp
• ALX Oncology Holdings Inc. Files 8-K on Shareholder Vote Matters — Jun 12, 2025 Risk: low
  ALX Oncology Holdings Inc. filed an 8-K on June 12, 2025, reporting on a submission of matters to a vote of security holders that occurred on June 11, 2025. The
• ALX Oncology Faces Delisting Notice — Apr 25, 2025 Risk: high
  ALX Oncology Holdings Inc. filed an 8-K on April 25, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule or standard, effective
• ALX Oncology Files 8-K for Financials — Mar 6, 2025 Risk: low
  ALX Oncology Holdings Inc. filed an 8-K on March 6, 2025, to report on its results of operations and financial condition, as well as to file financial statement
• ALX Oncology Reports Exit Costs and Officer Changes — Mar 5, 2025 Risk: medium
  ALX Oncology Holdings Inc. filed an 8-K on March 5, 2025, reporting on cost-associated exit or disposal activities and changes in directors and officers. The fi
• ALX Oncology Holdings Inc. Files 8-K with Board and Compensation Changes — Jan 22, 2025 Risk: medium
  ALX Oncology Holdings Inc. announced on January 16, 2025, changes in its board of directors and executive compensation arrangements. The filing also includes a
• ALX Oncology Holdings Inc. Reports Board and Executive Changes — Jan 17, 2025 Risk: medium
  ALX Oncology Holdings Inc. announced on January 16, 2025, changes in its board of directors and executive compensation arrangements. The filing details the depa
• ALX Oncology Holdings Inc. Announces Board Changes and Officer Compensation — Nov 14, 2024 Risk: medium
  On November 8, 2024, ALX Oncology Holdings Inc. filed an 8-K report detailing several key events. The company announced the departure of Director Dr. Michael J.
• ALX Oncology Files 8-K: Director Changes & Financials — Oct 4, 2024 Risk: medium
  ALX Oncology Holdings Inc. filed an 8-K on September 30, 2024, reporting on the departure of directors, election of new directors, appointment of officers, and
• ALX Oncology Holdings Inc. Files 8-K Report — Aug 8, 2024 Risk: low
  On August 8, 2024, ALX Oncology Holdings Inc. filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition, as
• ALX Oncology Reports Director/Officer Changes — Aug 6, 2024 Risk: medium
  ALX Oncology Holdings Inc. filed an 8-K on August 5, 2024, reporting changes in its board of directors and certain officers, along with updates on compensatory
• ALX Oncology Holdings Reports Shareholder Vote Matters — Jun 17, 2024 Risk: medium
  ALX Oncology Holdings Inc. filed an 8-K on June 17, 2024, reporting an event that occurred on June 12, 2024. This filing pertains to the submission of matters t
• ALX Oncology Announces Executive and Board Changes — May 2, 2024 Risk: medium
  ALX Oncology Holdings Inc. announced on April 28, 2024, changes in its board of directors and executive compensation. Specifically, Dr. Michael J. Yothers was a

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX